THYROLAR-3 Drug Patent Profile
✉ Email this page to a colleague
When do Thyrolar-3 patents expire, and when can generic versions of Thyrolar-3 launch?
Thyrolar-3 is a drug marketed by Allergan and is included in one NDA.
The generic ingredient in THYROLAR-3 is liotrix (t4;t3). Additional details are available on the liotrix (t4;t3) profile page.
US Patents and Regulatory Information for THYROLAR-3
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | THYROLAR-3 | liotrix (t4;t3) | TABLET;ORAL | 016807-003 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
